Table 1.
Clinicopathologic Features in the Primary (Memorial Sloan Kettering Cancer Center) and Validation (Association Française de Chirurgie) cohorts of Patients Resected for Intrahepatic Cholangiocarcinoma
| MSKCC cohort (n=189) | AFC cohort (n=522) | p Value | |
|---|---|---|---|
| Preoperative | |||
| Age at surgery, y (SD) | 65.4 (11.8) | 64 (11.7) | 0.35 |
| Female, n (%) | 114 (60.3) | 268 (51.3) | 0.04 |
| Hepatitis, n (%) | 18 (9.5) | 32 (6.1) | 0.14 |
| HBV | 9 (4.8) | NA | |
| HCV | 9 (4.8) | NA | |
| PSC/IBD, n (%) | 7 (3.7) | NA | |
| Imaging modality, n (%) | |||
| CT | 170 (89.9) | NA | |
| MRI | 114 (60.3) | NA | |
| US | 70 (37) | NA | |
| PET | 59 (31.2) | NA | |
| Preoperative tumor size, cm (SD) | 6.5 (3.6) | 6.8 (3.8) | 0.16 |
| Preoperative multiple tumor | 33 (17.5) | 79 (15.1) | 0.49 |
| Preoperative enlarged lymph node | 16 (8.5) | NA | |
| Total bilirubin, mg/L (SD) | 1.2 (3.1) | 1.55 (3.4) | <0.001 |
| CA19-9, U/mL (SD) | 1847.7 (5354.1) | 1547 (7101) | 0.001 |
| Neoadjuvant therapy, n (%) | 10 (5.3) | 34 (6.5) | 0.6 |
| Postoperative | |||
| Major resection, n (%) | 124 (65.6) | 401 (76.8) | 0.004 |
| Tumor size, cm (SD) | 6.9 (3.9) | 7.1 (4) | 0.9 |
| Multiple lesions, n (%) | 54 (28.6) | 187 (35.8) | 0.08 |
| Underlying liver, n (%) | 0.053 | ||
| Steatosis | 69 (36.5) | 142 (27.2) | |
| Cirrhosis | 9 (4.8) | 25 (4.8) | |
| Vascular invasion, n (%) | 0.6 | ||
| Absent | 121 (64) | 321 (61.5) | |
| Present | 68 (36) | 201 (38.5) | |
| Microvascular | 46 (24.3) | NA | |
| Macrovascular | 22 (11.6) | NA | |
| Perineural invasion, n (%) | 54 (28.6) | 124 (23.8) | 0.21 |
| Extrahepatic invasion, n (%)* | 22 (11.6) | 34 (6.5) | 0.012 |
| Morphologic subtype, n (%) | <0.001 | ||
| Mass-forming | 176 (93.1) | 367 (70.3) | |
| Periductal invasion | 13 (6.9) | 9 (1.7) | |
| Intraductal growth | - | 6 (1.1) | |
| Mixed subtype | - | 58 (11.1) | |
| Unknown | - | 82 (15.7) | |
| Margin status, n (%) | 0.006 | ||
| Negative | 152 (80.4) | 365 (69.9) | |
| Positive | 37 (19.6) | 157 (30.1) | |
| pN stage, n (%) | 0.22 | ||
| pNx | 97 (51.3) | 246 (47.1) | |
| pN0 | 71 (37.6) | 191 (36.6) | |
| pN1 | 21 (11.1) | 85 (16.3) | |
| Adjuvant therapy, n (%) | 51 (27) | 178 (34.1) | 0.084 |
*
Gallbladder excluded.
AFC, Association Française de Chirurgie; CA19-9, carcinogen antigen 19-9; CT, computed tomography; HBV, hepatitis B virus; HCV, hepatitis C virus; IBD, inflammatory bowel disease; MRI, magnetic resonance imaging; MSKCC, Memorial Sloan Kettering Cancer Center; PET, positron emission tomography; PSC, primary sclerosing cholangitis; US, ultrasonography.